Innoen Hartmann-Diac

Adult administration

Typically, 500 to 1,000 mL is administered as a slow intravenous infusion for adults. The infusion rate should be limited to no more than 0.5 g of glucose per kg of body weight per hour. The dosage and infusion rate should be adjusted appropriately according to age, weight, and symptoms.

This medication contains glucose, so caution should be exercised as it may cause thiamine (vitamin B1) deficiency during intravenous administration. When used alongside intravenous calcium preparations, it may react with ceftriaxone and form precipitates; therefore, this drug and ceftriaxone should not be administered simultaneously via the same infusion device. An allergic reaction may occur, so if symptoms of allergy or anaphylaxis develop, administration should be stopped immediately and appropriate treatment sought. Due to the presence of potassium, there is a risk of hyperkalemia, so patients with poor kidney function or heart disease should be particularly cautious and have their serum potassium levels regularly monitored. Hyperglycemia and hyperosmolar states could occur due to glucose content, so diabetic patients or those requiring blood sugar regulation should closely monitor their blood sugar levels. With high sodium and chloride content, electrolyte imbalances such as hypernatremia, hyperchloremia, and metabolic acidosis may occur; hence, patients with related conditions or risks should periodically check serum electrolytes and kidney function. Children, the elderly, and postoperative patients who are at risk of hyponatremia should use this drug with caution and notify healthcare providers immediately if symptoms of hyponatremia, such as headaches, vomiting, or seizures, occur. Patients with hypercalcemia or a history of calcium kidney stones should avoid this drug as it may increase calcium levels. This drug can cause fluid overload, so patients with heart failure or kidney disease must adjust infusion rates and volumes and monitor fluid status carefully. This drug should not be administered to patients with lactic acidosis, excessive fluid state, storage dehydration, hypernatremia, hyperglycemia, neonates, or those who are hypersensitive to this drug. It should be used with caution in patients with renal impairment, heart failure, hypertonic dehydration, obstructive uropathy, severe liver dysfunction, and hyponatremia while closely monitoring their condition. When administering this drug, regular monitoring of blood sugar, electrolytes, and fluid balance is necessary to prevent abnormalities. Interaction may occur when combined with other medications, particularly those causing hyperkalemia, lithium, digoxin, and those affecting blood glucose and electrolyte regulation. Special care is needed for pregnant women, breastfeeding women, neonates, children, and the elderly when administering this drug, and blood glucose and electrolyte status should be monitored closely. This drug should not be mixed with preparations containing phosphate or carbonate during preparation, and infection prevention measures must be taken by disinfecting the skin and equipment prior to administration. The infusion rate should be slow, and it should not be connected continuously to avoid air embolism. Storage should be in a sealed container to prevent air or moisture intrusion, and it is best stored at room temperature away from direct sunlight; unused portions must be discarded immediately after opening.

Serious side effects

• Anaphylaxis
• urticaria
• difficulty breathing
• generalized papules and erythema
• hyperkalemia
• hyperglycemia
• hyperosmolar hyperglycemia state
• hyponatremia
• hyponatremic encephalopathy
• cardiac arrest

Mild side effects

• Vomiting
• hypertension
• tachycardia
• fever
• rash
• itching
• chills
• blistering at the injection site
• extravasation
• venous thrombosis

This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is also advisable to store it in a cool room away from direct sunlight.

Appearance

A colorless, transparent injectable solution filled in a plastic container packed with high-density polyethylene that is partially transparent on the outside.

Package unit

500, 1000 milliliters